Please login to the form below

Not currently logged in
Email:
Password:

GSK pulls application for HES treatment

The EU marketing application for an HES product has been withdrawn following clinical benefit concerns

GlaxoSmithKline (GSK) has withdrawn the marketing authorisation application in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES), following feedback from the Committee for Medicinal Products for Human Use (CHMP) that additional data was needed to further demonstrate clinical benefits.

Mepolizumab, an investigational, humanised monoclonal antibody, was intended for the treatment of FIP1 negative HES (HES patients without the FIPL1-PDGRA fusion gene), to reduce or eliminate the need for corticosteroid therapy and to reduce eosinophil count. There are currently no approved therapies in the EU for FIP1 negative HES.

GSK plans to continue, where permitted, to support access to mepolizumab for patients with life-threatening HES through its ongoing compassionate use programme. Patients will receive the drug for as long as they and their doctor believe they are benefiting from the treatment.

"Research and development in HES is tremendously challenging," said David Gordon, VP Biopharm R&D at GSK. "It is a disease with very limited treatment options and this decision has been extremely difficult to take. Nevertheless, we are committed to exploring new options to develop mepolizumab as a treatment for HES," he added.

Withdrawal of the EU application for mepolizumab for the treatment of HES does not preclude GSK from filing an application at a later date and the company will continue to explore future options for the development of the product. Development programmes for the other potential indications, including severe asthma will continue as planned. 

30th July 2009

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

At 90TEN, our expertise resides in integrating public relations, medical education and patient engagement techniques to deliver solutions that help...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....